AstraZeneca said Thursday that its COVID-19 prophylaxis drug is 83% effective in reducing the risk of symptomatic COVID-19 infection six months after being given, indicating that the antibody cocktail can be used to prevent severe disease in individuals. can be used as an effective means. Not developing a strong immune response to COVID-19 vaccines.
According to AstraZeneca, an antibody therapy called AZD7442, was also 88% effective in reducing the risk of severe COVID-19 or death when administered to COVID-19-infected patients within three days of symptom onset.
A separate follow-up to the phase three trials of prophylaxis showed that the drug eliminated the risk of severe COVID-19 and death among all recipients at six months after a single dose.
The drugmaker noted that the trials used a 300 mg dose of AZD7442 to muscle individuals who had not been exposed to COVID-19.
Antibody cocktails may prove to be an effective tool to protect people who may not develop a strong immune response after receiving the COVID-19 vaccine.